U.S. markets close in 5 hours 46 minutes
  • S&P 500

    4,447.89
    -1.09 (-0.02%)
     
  • Dow 30

    34,779.23
    +14.41 (+0.04%)
     
  • Nasdaq

    14,973.42
    -78.82 (-0.52%)
     
  • Russell 2000

    2,246.91
    -12.13 (-0.54%)
     
  • Crude Oil

    73.56
    +0.26 (+0.35%)
     
  • Gold

    1,746.40
    -3.40 (-0.19%)
     
  • Silver

    22.30
    -0.38 (-1.67%)
     
  • EUR/USD

    1.1712
    -0.0034 (-0.29%)
     
  • 10-Yr Bond

    1.4490
    +0.0390 (+2.77%)
     
  • GBP/USD

    1.3680
    -0.0041 (-0.30%)
     
  • USD/JPY

    110.6890
    +0.3880 (+0.35%)
     
  • BTC-USD

    42,210.97
    -1,942.67 (-4.40%)
     
  • CMC Crypto 200

    1,051.73
    -51.33 (-4.65%)
     
  • FTSE 100

    7,069.34
    -9.01 (-0.13%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Voyager Therapeutics to Participate in Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, today announced that it will participate in the following upcoming virtual investor conferences.

  • Wells Fargo Securities Healthcare Conference, fireside chat, Sept. 9, 2021, 2:00 p.m. ET

  • Morgan Stanley Global Healthcare Conference, fireside chat, Sept. 14, 2021, 2:00 p.m. ET

  • Baird Global Healthcare Conference, company presentation, Sept. 15, 2021, 8:30 a.m. ET

The sessions may be accessed from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company’s TRACER™ screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurological disorders and other therapeutic areas.
voyagertherapeutics.com LinkedIn Twitter

Investor Inquiries:
investors@voyagertherapeutics.com

Media Inquiries:
Scott Santiamo
ssantiamo@voyagertherapeutics.com